Madhav Dhodapkar, MBBS

Dr. Madhav Dhodapkar is a hematologist-oncologist whose research focuses on developing novel immune-based methods of treating cancer, including cell-based approaches. Dr. Dhodapkar’s expertise centers around clinical/translational research in cancer immunology/dendritic cell (DC) biology and immunobiology of multiple myeloma (MM) and related diseases. He carried out the earliest studies of adoptive human DC transfer and in vivo targeting of human DCs. His lab has made seminal contributions to MM biology and cancer immunology, including leading the first clinical studies that led to the discovery of anti-myeloma effects of thalidomide and the first U.S. national cooperative group studies in precursor gammopathies and AL amyloidosis. Dr. Dhodapkar co-led the first Phase 3 studies showing successful prevention of clinical MM. He is an elected member of the American Society for Clinical Investigation and a recipient of several awards, including an NCI Outstanding investigator award and an NIH Director’s Transformative Research Award.